Free Trial

Verona Pharma PLC American Depositary Share (VRNA) Stock Price, News & Analysis

Verona Pharma PLC American Depositary Share logo
$105.80 +0.02 (+0.01%)
As of 01:29 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Verona Pharma PLC American Depositary Share Stock (NASDAQ:VRNA)

Key Stats

Today's Range
$105.71
$105.81
50-Day Range
$86.86
$105.80
52-Week Range
$24.50
$105.85
Volume
289,934 shs
Average Volume
2.23 million shs
Market Capitalization
$9.15 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$109.00
Consensus Rating
Hold

Company Overview

Verona Pharma PLC American Depositary Share Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
50th Percentile Overall Score

VRNA MarketRank™: 

Verona Pharma PLC American Depositary Share scored higher than 50% of companies evaluated by MarketBeat, and ranked 572nd out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Verona Pharma PLC American Depositary Share has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on 2 buy ratings, 12 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Verona Pharma PLC American Depositary Share has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Verona Pharma PLC American Depositary Share's stock forecast and price target.
  • Earnings Growth

    Earnings for Verona Pharma PLC American Depositary Share are expected to grow in the coming year, from ($1.95) to $0.03 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Verona Pharma PLC American Depositary Share is -106.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Verona Pharma PLC American Depositary Share is -106.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Verona Pharma PLC American Depositary Share has a P/B Ratio of 32.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Verona Pharma PLC American Depositary Share's valuation and earnings.
  • Percentage of Shares Shorted

    3.05% of the float of Verona Pharma PLC American Depositary Share has been sold short.
  • Short Interest Ratio / Days to Cover

    Verona Pharma PLC American Depositary Share has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Verona Pharma PLC American Depositary Share has recently decreased by 39.16%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Verona Pharma PLC American Depositary Share does not currently pay a dividend.

  • Dividend Growth

    Verona Pharma PLC American Depositary Share does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.05% of the float of Verona Pharma PLC American Depositary Share has been sold short.
  • Short Interest Ratio / Days to Cover

    Verona Pharma PLC American Depositary Share has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Verona Pharma PLC American Depositary Share has recently decreased by 39.16%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Verona Pharma PLC American Depositary Share has a news sentiment score of 1.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 11 news articles for Verona Pharma PLC American Depositary Share this week, compared to 9 articles on an average week.
  • Search Interest

    Only 4 people have searched for VRNA on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added Verona Pharma PLC American Depositary Share to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Verona Pharma PLC American Depositary Share insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $23,983,983.00 in company stock.

  • Percentage Held by Insiders

    Only 4.80% of the stock of Verona Pharma PLC American Depositary Share is held by insiders.

  • Percentage Held by Institutions

    85.88% of the stock of Verona Pharma PLC American Depositary Share is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Verona Pharma PLC American Depositary Share's insider trading history.
Receive VRNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verona Pharma PLC American Depositary Share and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

VRNA Stock News Headlines

Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.tc pixel
See More Headlines

VRNA Stock Analysis - Frequently Asked Questions

Verona Pharma PLC American Depositary Share's stock was trading at $46.44 on January 1st, 2025. Since then, VRNA shares have increased by 127.8% and is now trading at $105.7840.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) posted its quarterly earnings data on Wednesday, August, 6th. The company reported $0.13 EPS for the quarter, topping the consensus estimate of ($0.01) by $0.14. The company had revenue of $103.14 million for the quarter, compared to analyst estimates of $90.41 million. Verona Pharma PLC American Depositary Share had a negative trailing twelve-month return on equity of 21.12% and a negative net margin of 36.62%.

Verona Pharma PLC American Depositary Share (VRNA) raised $61 million in an IPO on Thursday, April 27th 2017. The company issued 4,500,000 shares at $13.49 per share. Jefferies and Stifel served as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers.

Top institutional shareholders of Verona Pharma PLC American Depositary Share include Perceptive Advisors LLC (6.47%), Frazier Life Sciences Management L.P. (3.98%), Eventide Asset Management LLC (3.19%) and Hood River Capital Management LLC (1.84%). Insiders that own company stock include David Zaccardelli, Mark W Hahn, Orbimed Advisors Llc, Kathleen A Rickard, Claire Poll, David R Ebsworth, Andrew Fisher, Martin Edwards, Vikas Sinha, Mahendra Shah, Lisa Deschamps, Kenneth Cunningham, James Aloysius Brady and Michael Austwick.
View institutional ownership trends
.

Shares of VRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Verona Pharma PLC American Depositary Share investors own include Cisco Systems (CSCO), Philip Morris International (PM), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Home Depot (HD) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
8/06/2025
Today
8/28/2025
Next Earnings (Estimated)
11/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:VRNA
CIK
1657312
Fax
N/A
Employees
30
Year Founded
N/A

Price Target and Rating

High Price Target
$170.00
Low Price Target
$57.00
Potential Upside/Downside
+3.0%
Consensus Rating
Hold
Rating Score (0-4)
2.14
Research Coverage
14 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.99)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$173.42 million
Net Margins
-36.62%
Pretax Margin
-32.91%
Return on Equity
-21.12%
Return on Assets
-9.07%

Debt

Debt-to-Equity Ratio
0.87
Current Ratio
10.71
Quick Ratio
10.54

Sales & Book Value

Annual Sales
$42.28 million
Price / Sales
216.41
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.22 per share
Price / Book
32.85

Miscellaneous

Outstanding Shares
86,500,000
Free Float
82,344,000
Market Cap
$9.15 billion
Optionable
Optionable
Beta
0.12

Social Links

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:VRNA) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners